Which snake bite causing a myasthenic syndrome is likely to improve with neostigmine (i.e., involves a post‑synaptic neurotoxin rather than presynaptic involvement)?

Answer

Neostigmine-responsive myasthenic syndrome is most characteristic of postsynaptic α-neurotoxin envenoming from cobras (Naja spp.) and certain coral snakes (e.g., Micrurus frontalis), not presynaptic kraits. 1, 2, 3

• Rationale (prioritizing morbidity, mortality, QOL):
  • Postsynaptic blockade (α-neurotoxins) at the nicotinic receptor can show clinical improvement with acetylcholinesterase inhibitors (e.g., neostigmine), which may hasten recovery of bulbar/respiratory weakness and reduce ventilation time when antivenom access/timing is limited 1, 3, 2.
  • Presynaptic neurotoxins (e.g., Bungarus caeruleus, common krait) destroy neuromuscular transmission; neostigmine is ineffective and patients typically require ventilation and antivenom support 4.

Practical algorithm (when facing neuroparalysis after snakebite)

• If clinical pattern suggests postsynaptic paralysis (ptosis, ophthalmoplegia, bulbar weakness progressing to respiratory failure; species likely cobra/coral; early after bite) → trial of neostigmine with anticholinergic:
  • Give atropine/glycopyrrolate first or concomitantly to prevent bradycardia per drug label; typical max total neostigmine dose 0.07 mg/kg IV (up to 5 mg), titrated to effect 5.
  • Proceed with definitive antivenom and airway/ventilatory support as needed (guidelines emphasize antivenom and urgent care) [6–6].
• If presynaptic pattern/known krait bite (Bungarus caeruleus) or no response to test doses → do not persist with neostigmine; prioritize antivenom and ventilation (neostigmine shown ineffective in krait envenoming) 4.

Nuances and caveats

• Evidence strength:
  • Human mechanistic/clinical data indicate postsynaptic cobra toxins (especially long-chain α-neurotoxins) drive paralysis and are not reliably reversed by AChE inhibitors alone; antivenom remains key. Limited case-based evidence supports neostigmine benefit in cobra/coral snake envenoming; strongest negative data exist for krait (presynaptic) where neostigmine fails 1, 4, 3, 2.
• Pitfalls to avoid:
  • Do not delay antivenom/airway management while trialing neostigmine (mortality risk) [6–6].
  • Always pair neostigmine with an anticholinergic to mitigate bradycardia/hypotension per FDA label 5.
  • Lack of improvement after a dose or two suggests presynaptic injury—stop neostigmine and focus on ventilation/antivenom 4.